A TNF-α-derived polypeptide, a nano-selenium complex peptide, its preparation method and application

By mutating the amino acid of TNF-α-derived peptide P16 and modifying it with chitosan to create a nano-selenium complex, SCP was prepared. This solved the problem of poor solubility of existing TNF-α-derived peptides, achieving anti-tumor effects with higher solubility, longer half-life, and fewer side effects, thus improving the efficacy of prostate cancer treatment.

CN117466987BActive Publication Date: 2026-11-10JINAN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311204545.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-19
Publication Date
2026-11-10
Estimated Expiration
2043-09-19

AI Technical Summary

Technical Problem

Existing TNF-α-derived peptides have poor solubility, poor stability, and short half-life, which limits their application in the treatment of prostate cancer. Furthermore, traditional treatment methods are ineffective for CRPC patients, and immunotherapy has not shown significant effects.

Method used

The amino acid sequence of TNF-α-derived peptide P16 was mutated using genetic engineering technology to form VP16, which was then combined with chitosan-modified selenium nanoparticles to prepare TNF-α-derived peptide and selenium nanoparticle complex peptide SCP. The solubility and stability were improved by using nanomedicine carrier technology.

Benefits of technology

It improved the solubility and stability of TNF-α-derived peptides, prolonged their half-life in vivo, enhanced their anti-tumor activity, reduced side effects, and significantly improved the therapeutic effect on prostate cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117466987B_ABST
    Figure CN117466987B_ABST
Patent Text Reader

Abstract

This invention discloses a TNF-α-derived polypeptide, a nano-selenium complex peptide, its preparation method, and its applications. Based on genetic engineering and nanoparticle drug delivery technologies, this invention significantly improves the solubility of the small molecule polypeptide P16 by mutating the first two LL amino acids at the N-terminus to generate the derivative polypeptide VP16. Secondly, using chitosan-modified selenium nanoparticles as a carrier, it is covalently coupled with the TNF-α-derived polypeptide VP16 to prepare the nano-selenium complex peptide, which exhibits advantages such as high antitumor activity, long half-life, high solubility, and few side effects. According to the results of nude mouse experiments with Du145 xenograft tumors, the polypeptide SCP has better pharmacodynamic effects and fewer toxic side effects than estradiol, a clinically used drug for prostate cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of genetic engineering, molecular biology, and biomedicine, and particularly to a TNF-α-derived polypeptide, a nano-selenium complex peptide, its preparation method, and its application. Background Technology

[0002] Prostate cancer is the second most common malignant tumor in men, with a peak incidence age of over 65. Incidence and mortality rates are positively correlated with age, and there is a significant trend towards younger onset. Due to its highly insidious nature, long latency period, and lack of obvious symptoms, prostate cancer is often diagnosed at an advanced stage, making it extremely difficult to cure and resulting in a short survival time. Prostate cancer is classified into localized prostate cancer, metastatic prostate cancer, and castration-resistant prostate cancer (CRPC) based on its progression. Almost all prostate cancer patients eventually develop CRPC, which is also a leading cause of death among these patients.

[0003] Prostate cancer is an androgen-dependent tumor. Besides traditional surgical treatment, radiotherapy, chemotherapy, hormone therapy, and targeted therapy, androgen deprivation therapy (ADT) has been the standard treatment for prostate cancer. While ADT can achieve good initial results, it disrupts the normal male endocrine environment, leading to certain complications, and it is ineffective for patients who have progressed to recurrent prostate cancer (CRPC). Furthermore, due to the low tumor mutation burden and lack of T-cell infiltration in prostate cancer, the immune response is weak. Clinical trials of CTLA-4 inhibitors, PD-1 / PD-L1 inhibitors, and combination therapies have all failed. Therefore, there is an urgent need to develop a prostate cancer treatment that can directly kill tumor cells and improve immunotherapy sensitivity to improve the quality of life for prostate cancer patients.

[0004] Tumor necrosis factor-alpha (TNF-α) is the most potent anti-tumor cytokine and the only one capable of directly killing tumor cells, making it highly promising for cancer treatment. The anti-tumor mechanisms of TNF-α mainly include inducing tumor cell apoptosis, inhibiting tumor angiogenesis, and enhancing the body's immunity. Furthermore, multiple studies have reported that TNF-α can increase tumor T-cell infiltration, improve vascular permeability, and assist drugs and immune cells in crossing the tumor barrier and entering the tumor. However, at effective anti-tumor concentrations, TNF-α can cause very strong systemic toxicity, significantly limiting the development of TNF-α anticancer drugs. Our research group previously developed a small molecule polypeptide, P16, that specifically activates the receptor TNFRI by comparing TNF-α sequences from various vertebrates, reducing its side effects. However, its poor solubility, instability, and short half-life (5-10 min) limit its clinical application value. Summary of the Invention

[0005] The primary objective of this invention is to overcome the shortcomings and deficiencies of the prior art and provide a TNF-α-derived polypeptide. This TNF-α-derived polypeptide exhibits higher solubility.

[0006] Another object of the present invention is to provide a nano-selenium complex peptide. This nano-selenium complex peptide has higher solubility, anti-tumor activity, longer half-life, and fewer side effects.

[0007] The objective of this invention is achieved through the following technical solution:

[0008] A TNF-α-derived polypeptide with the following amino acid sequence: VVTHTISRIAVSYQTKVNLL.

[0009] A nucleic acid molecule encoding the aforementioned TNF-α-derived polypeptide; preferably as shown below:

[0010] GTGGTGACCCATACCATTAGCCGCATTGCGGTGAGCTATCAGACCAAAGTGAATCTG CTG.

[0011] The TNF-α-derived polypeptide can be obtained by direct synthesis or by cloning the above nucleic acid molecules into an expression vector, transforming the resulting recombinant vector into host cells for expression; then, the bacterial cells are collected and broken, and the supernatant of the broken bacterial solution is collected and purified to obtain the TNF-α-derived polypeptide.

[0012] The preferred expression vector is the pKYB vector.

[0013] The preferred host cell is Escherichia coli ER2566.

[0014] The preferred expression procedure is as follows: after expanding the culture of host cells containing the recombinant vector, IPTG is added to induce expression.

[0015] The conditions for the expanded culture are preferably 35-38℃ and 150-250rpm; more preferably 37℃ and 200rpm.

[0016] The preferred extent of the expanded culture is to culture to OD. 600 It is 0.6.

[0017] The preferred conditions for inducing expression are 35–38°C and 150–250 rpm for 4–8 hours; more preferably, 37°C and 200 rpm for 6 hours.

[0018] The preferred method for cell disruption is to use a low-temperature, ultra-high-pressure continuous flow cell disruptor.

[0019] The purification is performed using a chitin column; the preferred specific operation is as follows: the supernatant is loaded into a chitin column, then a solution containing thiol is added to pass through the column and the column is filled with the chitin column environment for reaction and elution;

[0020] The composition of the thiol-containing solution is as follows: 20 mM Tris-HCl, 0.5 mM NaCl, 1 mM EDTA, 50 mM β-mercaptoethanol, pH 8.0;

[0021] The elution solution has the following composition: 20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, pH 8.0.

[0022] A nano-selenium complex peptide is obtained by modifying nano-selenium with polysaccharides to load and activate TNF-α-derived peptides; preferably, it is prepared through the following steps:

[0023] (1) The activated TNF-α-derived peptide solution was added dropwise to the polysaccharide-modified selenium nanoparticles and the reaction was stirred.

[0024] (2) The reaction product was dialyzed to obtain nano-selenium complex peptide.

[0025] The preferred conditions for the stirring reaction in step (1) are 2-8°C and 100-500 rpm for 8-12 hours; more preferably, 4°C and 300 rpm for 8-12 hours.

[0026] The polysaccharide-modified selenium nanoparticles are preferably prepared by the following steps: sodium selenite and polysaccharide are mixed evenly in water, and a reducing agent is added to react; after the reaction is completed, dialysis is performed to obtain polysaccharide-modified selenium nanoparticles.

[0027] The polysaccharide is preferably chitosan.

[0028] The amount of chitosan added is calculated based on a mass ratio of sodium selenite to polysaccharide of 9 to 11:1; more preferably, it is calculated based on a mass ratio of sodium selenite to polysaccharide of 10:1.

[0029] The reducing agent is preferably ascorbic acid.

[0030] The reducing agent is added to the reaction system dropwise. Addition of the reducing agent is stopped when the color of the reaction product no longer changes.

[0031] The reaction was carried out under light-protected conditions.

[0032] The activated TNF-α-derived polypeptide is preferably obtained through the following steps: dissolving the TNF-α-derived polypeptide in DMSO and then making up the volume with water, followed by adding an amide activator to react and obtain the activated TNF-α-derived polypeptide.

[0033] The preferred dosage of DMSO is 2-3 μL per mg of TNF-α-derived polypeptide.

[0034] The preferred volume for making up the volume is 1 mL for every 1-3 mg of TNF-α-derived polypeptide.

[0035] The amide activator is an amide activator obtained by EDC and NHS in a mass ratio of 1.5 to 2.5:1; preferably, it is an amide activator obtained by EDC and NHS in a mass ratio of 2:1.

[0036] The amount of the amide activator is preferably in a mass ratio of TNF-α derived peptide: amide activator of 10:1 to 2; more preferably in a mass ratio of TNF-α derived peptide: amide activator of 10:1.

[0037] The preferred reaction conditions are 2–8°C and stirring at 100–500 rpm for 60–180 min; more preferably, 4°C and stirring at 300 rpm for 120 min.

[0038] The polysaccharide-modified selenium nanoparticles and the activated TNF-α-derived polypeptide are preferably calculated as follows: the mass ratio of polysaccharide in the polysaccharide-modified selenium nanoparticles to the activated TNF-α-derived polypeptide is 0.08:1.5-2.5; more preferably, the mass ratio of polysaccharide in the polysaccharide-modified selenium nanoparticles to the activated TNF-α-derived polypeptide is 0.08:2.

[0039] The above-mentioned TNF-α-derived peptides or nano-selenium complex peptides are used in the preparation of drugs for treating diseases associated with TNFR type I receptors.

[0040] The diseases associated with TNFR type I receptor include prostate cancer.

[0041] The drug exerts the following effects: promoting tumor cell apoptosis, promoting tumor cell cycle arrest, and inhibiting tumor angiogenesis.

[0042] The present invention has the following advantages and effects compared with the prior art:

[0043] This invention, based on genetic engineering and nanoparticle drug delivery technologies, significantly improves the solubility of P16 by mutating the first two LL amino acids at the N-terminus of the small molecule peptide P16 to generate a derived peptide VP16. Secondly, using chitosan-modified selenium nanoparticles (SeNPs-CTS, SC) as a carrier, it is covalently coupled with the TNF-α derived peptide VP16 to prepare a TNF-α derived peptide / selenomeric nanoparticle complex peptide (SeNPs-CTS-VP16, SCP), which exhibits advantages such as high antitumor activity, long half-life, high solubility, and few side effects.

[0044] (1) The TNF-α-derived polypeptide and nano-selenium complex peptide SCP prepared in this invention are recombinant derivatives of natural TNF-α, containing the core anti-tumor sequence of TNF-α, and SCP has higher targeting and anti-tumor activity than natural TNF-α.

[0045] (2) The recombinant polypeptide SCP overcomes the drawback of poor solubility of the previous TNF-α-derived polypeptide P16. By performing site-directed mutation on the first two amino acids at the N-terminus of polypeptide P16, the solubility of SCP is significantly improved.

[0046] (3) This invention utilizes nanomedicine carrier technology. On the one hand, its sustained-release function can significantly increase the half-life of the drug in vivo; on the other hand, nano-selenium itself has excellent anti-tumor properties. In addition, this invention also uses chitosan to modify nano-selenium (SC) to increase the stability of the nano-selenium-loaded drug. By coupling SC with the TNF-α-derived polypeptide VP16, a dual anti-tumor effect is achieved. Attached Figure Description

[0047] Figure 1 The figure shows the solubility analysis results of VP16 peptide; where (A) is the standard curve after serial dilution of bovine serum albumin; and (B) is the absorbance of each group at 562 nm.

[0048] Figure 2 The image shows the weight results of the tumors in each group.

[0049] Figure 3 HE staining (200×) results for five organs and tumors in each group. Detailed Implementation

[0050] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the embodiments of the present invention are not limited thereto.

[0051] Unless otherwise specified, the following implementation schemes generally follow standard experimental conditions or the experimental conditions recommended by the reagent company. Unless otherwise specified, all materials and reagents used are commercially available. Example 1: Preparation of Recombinant Nano-Selenium Complex Peptide SCP for the Treatment of Prostate Cancer

[0052] In the previous study, the TNF-α sequences of nine vertebrate species were compared, and a TNF-α-derived polypeptide P16 with good antitumor activity was obtained. The amino acid sequence is as follows: LLTHTISRIAVSYQTKVNLL, whose nucleotide sequence is shown in SEQ ID NO.4. Based on this, two amino acids of LL (underlined in the sequence) were mutated at a specific site, and then linked to chitosan-modified selenium nanoparticles (SeNPs-CTS, SC) via amide bonds to form SCP (SeNPs-CTS-VP16).

[0053] The preparation method is as follows:

[0054] (1) Amino acid site-directed mutagenesis: LL amino acids were designed for site-directed mutagenesis. Based on the primer design principles and the kit instructions, three primers were designed using Primer X design of mutagenic primers for site-directed mutagenesis. Overlap PCR was used to perform chain extension reaction first and then PCR reaction to obtain the VP16 gene.

[0055] Primer F1:

[0056] 5'-GGTGGT CATATGGTGGTG ACCCATACCATTAGCCGC-3';

[0057] Primer F2:

[0058] 5'-GGTCTGATAGCTCACCGCAATGCGGCTAAT-3';

[0059] Primer F3:

[0060] 5'-CCACCAT GCTCTTCCGCA CAGCAGATTCACTTTGGTCTG-3'.

[0061] in, CATATG This is the Nde I restriction site. GCTCTTCCGCA This is the BspQⅠ restriction site; GGTGGT and CCACCAT are protective bases; among them, GTGGTG This is the mutated sequence.

[0062] The chain extension reaction system consisted of: 2 μL of primer F1 (10 μM), 2 μL of primer F2 (10 μM), and 10× TaKaRa LA PCR Buffer (Mg). 2+ plus)5μL, dNTP8μL, TaKaRa LA Taq0.5μL, H2O 32.5μL.

[0063] The extended reaction conditions were: 94℃ for 10 min, 60℃ for 5 min, and 72℃ for 10 min.

[0064] The PCR (50 μL) reaction system was constructed as follows: primer F1 (10 μM) 2 μL, primer F3 (10 μM) 2 μL, extension reaction solution 1 μL, dNTP 4 μL, 10×TaKaRa Ex Buffer 5 μL, TaKaRaTaq 0.5 μL, and H2O 36.5 μL.

[0065] The reaction conditions were: 94℃ for 5 min; 31 cycles of 94℃ for 30 s, 60℃ for 30 s, and 72℃ for 30 s; and an extension at 72℃ for 10 min. After PCR, 3 μL was subjected to agarose gel electrophoresis to observe the results. The resulting phase was then purified to obtain the PCR product.

[0066] (2) Construction of recombinant expression vector pKYB-VP16: The PCR product obtained in the previous step and vector pKYB1 (New England Biolabs (NEB)) were digested with NdeI and BspQI (isoenzymes of SapI, New England Biolabs (NEB)). The digested vector pKYB1 was subjected to agarose gel electrophoresis and purified by gel extraction. The double-digested VP16 gene and the gel-extracted vector pKYB1 were ligated to establish a ligation system and form the pKYB-VP16 recombinant plasmid.

[0067] (3) Construction of engineered bacteria: Competent cells of Escherichia coli ER2566 were prepared using the CaCl2 method. The recombinant plasmid pKYB-VP16 was added to the competent cell suspension, mixed, and incubated on ice for 20 min. The mixture was then heat-shocked at 42℃ for 60 s, and preheated to 37℃ in SOC medium was added. The mixture was then incubated on a shaker at 37℃ for 45 min. 200 μL of the transformed bacterial solution was evenly spread on an LB agar plate (containing 100 μg / mL kanamycin). After standing for about 20 min until the liquid dried, the plate was inverted and incubated at 37℃ for 13-16 h until obvious colonies appeared.

[0068] (4) Screening and identification of positive clones: After transformation, positive single colonies were picked and placed in 5 mL LB medium (containing 100 μg / mL kanamycin), and cultured at 37℃ and 220 rpm for 12 h. After plasmid extraction, PCR identification was performed, and plasmid DNA was sequenced and verified using T7 promoter primers (BGI Genomics), resulting in engineered bacteria pKYB-VP16-ER2566.

[0069] (5) Induction of recombinant fusion protein VP16-intein-CBD: The engineered strain pKYB-VP16-ER2566 was inoculated into two 200 mL LB medium bottles (containing 100 μg / mL kanamycin) at a volume ratio of 1:100 and cultured at 37℃ with a shaker at 200 rpm until OD. 600To achieve a final concentration of approximately 0.6, isopropyl-β-D-thiogalactoside (IPTG) was added to one culture flask to a final concentration of 1 mM. The other flask served as a negative control without IPTG. Expression was induced at 37°C and 200 rpm for 6 h, followed by centrifugation at 6000 rpm for 15 min, and the bacterial cells were collected. The bacterial cells were resuspended at m / V (g / mL) = 1 / 10 in Buffer A solution (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 1 mM EDTA, 0.1% Triton-X100). The cells were then disrupted using a low-temperature, high-pressure continuous flow cell disruptor. The disruption conditions were: Buffer A solution diluted the bacterial cells to 18% (m / v), disruption pressure 1700 bar, and cooling temperature 4°C. The disrupted product was centrifuged at 4°C and 20000 rpm for 30 min, and the supernatant was collected. The expression of the fusion protein VP16-intein-CBD was detected by 12% SDS-PAGE electrophoresis.

[0070] (6) Purification and preparation of the peptide-mediated recombinant polypeptide VP16: The supernatant collected in step (5) was passed through a chitin column, and then through a solution containing thiol. The column was filled with thiol and reacted at 16°C for 24 h. The target peptide was collected by elution and identified by electrophoresis. The genetically engineered polypeptide VP16 was prepared by high performance liquid chromatography (HPLC) and its purity was analyzed. The prepared target peptide was freeze-dried. The composition of the thiol-containing solution was as follows: 20 mM Tris-HCl, 0.5 mM NaCl, 1 mM EDTA, 50 mM β-mercaptoethanol, pH 8.0, and deionized water was used as the solvent. The composition of the solution used to elute the chitin column was as follows: 20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, pH 8.0, and deionized water was used as the solvent. The HPLC procedure is as follows: Mobile phase A was obtained by adding trifluoroacetic acid (TFA) to 10% (v / v) acetonitrile (CNCH, solvent is pure water), with a final TFA concentration of 0.1% (v / v); Mobile phase B was obtained by adding TFA to 100% (CNCH), with a final TFA concentration of 0.1% (v / v); the flow rate was 1 mL / min, and linear gradient elution was performed for 20 min; during linear gradient elution, the elution peak of the target peptide was collected from 0% to 60% (v / v) of mobile phase B, and the light absorption detection wavelength was 218 nm.

[0071] (7) Preparation of nano-selenium carrier SC: Add 1 mL of 5 mM sodium selenite solution to a clean, sterile beaker, then add 100 μL of 0.8 mg / mL chitosan solution, mix well and let stand, then add 1 mL of 20 mM ascorbic acid solution dropwise while shaking (preferably in the dark), stir with a magnetic stirrer at 300 rpm for about 5-10 min, until the color no longer deepens, place it at 4℃ and let stand for about 30 min, then put it into a dialysis bag with a molecular weight cutoff of 6000-8000D, dialyze at 4℃ for 8-12 h to obtain chitosan-modified nano-selenium carrier SC. The preparation steps for Na2SeO3 (5mM) are as follows: Weigh 8.7mg of Na2SeO3 powder, dissolve it in an appropriate amount of ultrapure water, and then make up the volume to 10mL. Store at 4℃ in the dark. The preparation steps for Vc solution (20mM) are as follows: Weigh 35.2mg of Vc powder, dissolve it in an appropriate amount of ultrapure water, and then make up the volume to 10mL. Store at 4℃ in the dark. The preparation steps for CTS solution (0.8mg / mL) are as follows: Weigh 8mg of chitosan CTS powder, dissolve it in 1% glacial acetic acid solution, and then make up the volume to 10mL. Store at 4℃.

[0072] (8) Preparation of VP16 peptide solution: Weigh 2 mg of the peptide obtained in step (6), add 5 μL of DMSO to dissolve it, make up to 1 mL with ultrapure water, and add 0.2 mg of EDC / NHS (mixed evenly in a ratio of m / m = 2:1) amide activator. Stir at 4℃ and 300 rpm for 2 h to obtain VP16 peptide solution.

[0073] (9) Preparation of nano-selenium complex peptide SCP: Add the nano-selenium carrier SC solution prepared in step (7) to a clean and sterile beaker, add the VP16 polypeptide solution obtained in step (8) dropwise, and make up to 5 mL with ultrapure water. Stir at 4℃ and 300 rpm for 8-12 h. Dialyze for 12 h in a dialysis bag with a molecular weight cutoff of 6000-8000D to remove unreacted substances, and obtain nano-selenium complex peptide SCP. Determine the selenium content in the mutant SCP by ICP-AES and the polypeptide content by HPLC. The HPLC procedure for determining peptide release was as follows: 5 mg of SCP powder was dissolved in 5 mL of PBS (pH 7.4, 0.01 mol / L) and placed in a dialysis bag with the same cutoff volume. The bag was then placed in a hard glass tube containing 50 mL of PBS solution and shaken uniformly at 37°C. Every 2 hours, 1 mL of PBS solution was aspirated and an equal volume of fresh PBS solution was added back. The concentration of VP16 peptide was detected using an HPLC system (Agilent 1100) equipped with a μ-Bondapak C18 (4 × 300 mm) column, and the drug release was calculated. The detection wavelength was set to 225 nm. The mobile phase was prepared by mixing 125 mL of acetonitrile with 875 mL of 0.05 mM potassium dihydrogen phosphate buffer (pH 6.0) in a 1 mL vacuum flask, and the flow rate was set to 1.0 mL / min.

[0074] Example 2: Solubility Analysis of VP16

[0075] VP16 was prepared according to the preparation method of Example 1 (steps (1) to (6)); and nano-selenium complex peptide SCP was prepared according to the preparation method of Example 1 (steps (1) to (9)).

[0076] TNF-α and estramustine (Est) were purchased from Phamacia, Italy, and peptide P16 was synthesized by Bio-Thera Solutions (Guangzhou) Co., Ltd.

[0077] To determine its solubility, the specific procedure is as follows:

[0078] (1) Weigh 10mg of each sample and add it to a test tube. Add 5mL of physiological saline and let it dissolve evenly.

[0079] (2) Place the test tube in a 37°C constant temperature shaker and shake it evenly at 125 rpm to fully dissolve the polypeptide.

[0080] (3) The solution was filtered through a 0.22 μm filter membrane to remove impurities and undissolved polypeptide particles.

[0081] (4) Prepare BCA working solution according to the ratio of solution A: solution B = 50:1. Dilute the standard protein sequentially with distilled water to the following concentrations: 2000, 1000, 500, 250, 0 μg / mL. Take 10 μL of the filtrate obtained in step (3), add 20 μL of distilled water to each well to dilute the sample protein 3 times, and shake to mix.

[0082] (5) Take 10 μL of diluted standard protein and sample protein, and add 200 μL of BCA working solution. Place the 96-well plate in a 37°C incubator and incubate in the dark for 30 min. Detect the absorbance of each well at 450 nm using a microplate reader. The higher the absorbance, the higher the protein concentration in the filtrate and the better the solubility of the protein.

[0083] The results are as follows Figure 1 As shown, Figure 1 (A) in the figure represents the standard curve obtained by measuring the OD values ​​at 562 nm after serial dilution of 2000 μg / mL bovine serum albumin standard. Its R0 is... 2 The closer the result is to 1, the more reliable it is. Figure 1 (B) in the figure represents the OD value of each group measured at 562 nm. The results show that the OD value of the VP16 group is significantly increased compared with that of P16, and the concentration in physiological saline is higher, indicating that VP16 has higher solubility than P16.

[0084] Example 3: In vivo half-life study of nano-selenium complex peptide SCP at the animal level

[0085] (1) 264 Kunming mice (from Guangdong Provincial Medical Experimental Animal Center) weighing 25-30g were randomly divided into four groups of 66 mice each.

[0086] (2) At the same time, mice in each group were injected with SCP, VP16, P16 and TNF-α via the tail vein, with an injection dose of 5 mg / kg. Then each group was randomly divided into eleven subgroups, and blood samples were collected at time points of 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 16 h, 24 h and 48 h.

[0087] (3) The OD values ​​of serum mutant SCP, VP16, P16 and TNF-α in each group at different time points were detected according to the ELISA kit instructions.

[0088] (4) The content of each group was calculated according to the standard curve of the ELISA kit, and the half-life of the four drugs in Kunming mice was simulated using the pharmacokinetic software 3p97.

[0089] The pharmacokinetic parameters in vivo are shown in Table 1. The half-life of SCP in vivo was 13.52 h, while that of TNF-α was only 25.8 min, consistent with the reported half-life of TNF-α of only 30 min. This indicates that VP16, loaded with the carrier SC, effectively prolonged its half-life in vivo. The area under the plasma concentration-time curve (AUC) of SCP was 11.1 times that of VP16; while the plasma clearance (CL) of VP16 was 11.8 times that of SCP, indicating that the clearance rate of SCP in vivo was much lower than that of VP16. These results demonstrate that the carrier SC can significantly prolong the half-life of VP16 in vivo, thereby maximizing its therapeutic effect.

[0090] Table 1. Pharmacokinetic parameters in mice

[0091]

[0092] Example 4: Study on the effects and toxic side effects of nano-selenium complex peptide SCP on DU145 xenograft tumors in nude mice.

[0093] To investigate whether SCP also has an inhibitory effect on tumor growth in animals and its toxic side effects on organs, negative tumor mice were obtained by transplanting human prostate cancer cells DU145 (derived from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences) prepared in previous experiments into the armpits of nude mice as a model of transplanted tumors.

[0094] (1) Select 40 male BALB / c-nu nude mice (from Guangdong Provincial Medical Experimental Animal Center), 4 weeks old, weighing 18-20g. After the nude mice are kept in isolation for one week, if they are growing well, eating and drinking normally, and there are no abnormal symptoms, the model of subcutaneous xenograft tumor can be prepared.

[0095] (2) Collect DU145 cells in good logarithmic growth phase and place them on ice. Disinfect the skin on the right back of the nude mice in the experimental group with alcohol swabs, and subcutaneously inject 100 μL of cell suspension (1×10⁻⁶) into the axilla of each BALB / c-nu nude mouse. 7 (Number of cells). Injected cells should be processed within 30 minutes to avoid affecting cell viability. One week after cell inoculation, tumors measuring 50 mm in size were observed growing in the axillae of nude mice, with a tumor formation rate of 100%.

[0096] (3) After successful modeling, the animals were randomly divided into 8 groups, with 5 animals in each group. The animals were given the medication according to the table below, once a day for 30 days. The Se group was a single nano-selenium carrier (the specific preparation steps were the same as step (7) in Example 1, except that chitosan CST modification was not added).

[0097] Table 2. Drug administration procedures for each group of mice

[0098]

[0099] (4) Observe the tumor size and weight changes of nude mice. After treating the mice, blood samples were collected from the orbital cavity (heparin sodium blood collection tube) and tested. The samples were left to stand for 30 minutes, centrifuged at 10,000 rpm for 15 minutes, and the serum was placed in an EP tube and immediately sent to the Department of Laboratory Medicine of the First Affiliated Hospital of Jinan University for blood biochemical index testing. The heart, liver, spleen, lung and kidney organs of each mouse in each group were removed, calculated and stained with HE.

[0100] Changes in tumor weight in each group are as follows Figure 2 As shown in the results, excluding TNF-α-induced inflammatory necrosis, SCP exhibited the highest average tumor inhibition rate, exceeding 50%, indicating that the nano-selenium complex peptide SCP has a good growth inhibitory effect on DU145 prostate cancer xenografts in nude mice, followed by VP16 and Est. The results also show that both SeNPs and SC alone have certain tumor-inhibiting effects. The carrier SC effectively prolonged the half-life of VP16 in vivo, reduced renal clearance, and the combination of the two can achieve a synergistic anti-tumor effect.

[0101] In addition, based on HE staining analysis of five organs from each group of nude mice, the results are as follows: Figure 3 As shown, the nano-selenium complex peptide SCP did not significantly damage or impair liver and kidney function in transplanted tumor-bearing nude mice, indicating its safety in vivo. In contrast, the positive control drugs Est and TNF-α caused some damage to hepatocytes, leading to significant impairment of liver synthetic function. Furthermore, no significant toxic side effects were observed in the other five organs.

[0102] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A TNF-α-derived polypeptide, characterized in that: The amino acid sequence of the TNF-α-derived polypeptide is shown in SEQ ID NO.

1.

2. A nucleic acid molecule, characterized in that: The nucleic acid molecule described is a nucleic acid encoding the TNF-α-derived polypeptide of claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that: The sequence of the nucleic acid molecule is shown in SEQ ID NO.

2.

4. The method for preparing the TNF-α-derived polypeptide according to claim 1, characterized in that... The procedure includes the following steps: cloning the nucleic acid molecule as described in claim 2 into an expression vector, transforming the resulting recombinant vector into a host cell for expression; then collecting and disrupting the bacterial cells, collecting the supernatant of the disrupted bacterial solution for purification, and obtaining a TNF-α-derived polypeptide.

5. The method for preparing the TNF-α-derived polypeptide according to claim 4, characterized in that: The expression vector is a pKYB vector; The host cell was Escherichia coli ER2566; The expression process is as follows: host cells containing the recombinant vector are cultured in a large-scale manner, and then IPTG is added to induce expression. The purification process described above involved using a chitin column.

6. The method for preparing the TNF-α-derived polypeptide according to claim 5, characterized in that: The conditions for the expanded culture were culture at 35–38°C and 150–250 rpm. The extent of the expanded culture is defined as culture to OD. 600 It is 0.6; The conditions for inducing expression are: induction at 35–38°C and 150–250 rpm for 4–8 hours; The specific purification procedure is as follows: the supernatant is loaded into a chitin column, and then a solution containing thiol is added to pass through the column and fill the chitin column environment for reaction and elution. The composition of the thiol-containing solution is as follows: 20 mM Tris-HCl, 0.5 mM NaCl, 1 mM EDTA, 50 mM β-mercaptoethanol, pH 8.0; The elution solution composition is as follows: 20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, pH 8.

0.

7. A nano-selenium complex peptide, characterized in that: It is obtained by covalently coupling polysaccharide-modified selenium nanoparticles with the activated TNF-α-derived polypeptide described in claim 1; The polysaccharide mentioned is chitosan.

8. The nano-selenium complex peptide according to claim 7, characterized in that: The polysaccharide-modified selenium nanoparticles were prepared by the following steps: sodium selenite and polysaccharide were mixed evenly in water, and a reducing agent was added to react; after the reaction was completed, dialysis was performed to obtain polysaccharide-modified selenium nanoparticles. The activated TNF-α-derived polypeptide was obtained through the following steps: the TNF-α-derived polypeptide was dissolved in DMSO and then diluted with water to a final volume. Then, an amide activator was added to react and the activated TNF-α-derived polypeptide was obtained. The polysaccharide-modified selenium nanoparticles and the activated TNF-α-derived polypeptides are calculated according to a mass ratio of polysaccharide in the polysaccharide-modified selenium nanoparticles to activated TNF-α-derived polypeptides of 0.08:1.5-2.

5.

9. The nano-selenium complex peptide according to claim 8, characterized in that: The amount of polysaccharide added is calculated based on a mass ratio of sodium selenite to polysaccharide of 9-11:

1. The reducing agent is ascorbic acid; The reducing agent is added to the reaction system dropwise. The reaction was carried out under light-protected conditions; The amide activator is an amide activator obtained by mixing EDC and NHS at a mass ratio of 1.5 to 2.5:1; The amount of the amide activator is adjusted according to a mass ratio of TNF-α derived peptide: amide activator of 10:1 to 2.

10. The use of the TNF-α-derived polypeptide of claim 1 or the nano-selenium complex peptide of any one of claims 7 to 9 in the preparation of a drug for treating prostate cancer.

Citation Information

Patent Citations

  • Long-acting nanometer composite peptide resistant to II-type diabetes and preparing method and application of long-acting nanometer composite peptide

    CN104138602A

  • Gene-recombined TNF-alpha derivative RMP16 and preparation method and application thereof

    CN104177489A